Regorafenib plus avelumab in advanced neuroendocrine tumors — and the IDO1 biomarker that predicts resistance
How mature TLSs identify solid tumor patients more likely to benefit from PD-1 blockade
How plasma LIF predicts immune-checkpoint blockade resistance and a TLS-poor tumor microenvironment
